Ironwood Pharmaceuticals (IRWD) Free Cash Flow (2010 - 2026)

Ironwood Pharmaceuticals has disclosed Free Cash Flow across 17 years of filings, most recently posting $5.1 million for Q1 2026.

• Free Cash Flow for Q1 2026 came in at $5.1 million, down 74.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $112.2 million (up 43.1% YoY), and the FY2025 annual result was $127.0 million, up 22.83% from the prior year.
• Free Cash Flow came in at $5.1 million for Q1 2026 at Ironwood Pharmaceuticals, down from $74.6 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $80.2 million in Q1 2023 to a low of -$15.1 million in Q2 2025.
• The 5-year median for Free Cash Flow is $35.6 million (2023), against an average of $40.7 million.
• Peak annual rise in Free Cash Flow reached 390.18% in 2025, while the deepest fall reached 145.11% in 2025.
• Ironwood Pharmaceuticals' Free Cash Flow stood at $79.2 million in 2022, then tumbled by 55.03% to $35.6 million in 2023, then sank by 57.29% to $15.2 million in 2024, then soared by 390.18% to $74.6 million in 2025, then slumped by 93.13% to $5.1 million in 2026.
• The last three Free Cash Flow figures came in at $5.1 million (Q1 2026), $74.6 million (Q4 2025), and $47.6 million (Q3 2025), per Business Quant data.